Philips submits helium-free 3T MRI platform to the FDA
BlueSeal Horizon is under review, not cleared; “helium-free” describes operation with helium sealed inside the magnet.

Philips has submitted its 3.0-tesla BlueSeal Horizon SI, XI and ZI systems for FDA 510(k) review. The November 17 announcement marks an application, not a clearance.
The company aims to extend its BlueSeal technology to 3T MRI. According to the source, BlueSeal Horizon is not yet available for sale in any jurisdiction. “Helium-free” refers to operation: seven liters of helium remain permanently sealed in the cryogenic circuit, so the platform is not literally devoid of helium.
Context and evidence
Philips cites more than 2,500 installed 1.5T BlueSeal systems and estimates savings of more than seven million liters of helium against an older 1,500-liter magnet generation. These are manufacturer calculations. Experience with the 1.5T portfolio is separate from the ongoing regulatory process for the 3T platform; no firm FDA decision date is given.
What it means
The approach is relevant to long-term MRI planning, helium supply and installation. For now, the new platform remains a proposed option subject to regulatory review, not a US system available for immediate procurement.
Primary source: Original announcement. This report is based on company statements, not an independent clinical assessment.
More from Regulation
AI illustrationFDA clears AI software for coronary CT analysis
Syngo.CT Coronary Cockpit analyzes plaque and supports intervention planning. The clearance applies to the US market.
AI illustrationHugo surgical robot gains US clearance for general surgery
Medtronic expands the US indications for its robotic-assisted surgery platform; clearance is not proof of superior outcomes.
AI illustrationFDA clears MiniMed Fit tubeless insulin pump
The company plans a phased US launch in spring 2027 following clearance for users aged seven and older.